<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35661277</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>OPTN variants in ALS cases: a case report of a novel mutation and literature review.</ArticleTitle><Pagination><StartPage>5391</StartPage><EndPage>5396</EndPage><MedlinePgn>5391-5396</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06125-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Optineurin (OPTN)-associated mutations have been implicated in the development of type 12 amyotrophic lateral sclerosis (ALS12). We reported a case of ALS with a new OPTN variant (p.D527fs) and reviewed relevant literature to better understand the phenotypes and pathophysiological mechanisms of ALS12.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We report a case of a 55-year-old female patient with a new heterozygous variant of the OPTN gene. A literature search of ALS cases associated with the OPTN gene mutations was performed in PubMed with the search criteria as [("amyotrophic lateral sclerosis") OR ("motor neuron disease")] AND ("OPTN").</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The case of ALS with a new OPTN variant (p.D527fs) in our report manifested with bulbar involvement in onset and a rapidly progressive course. A literature review of 37 ALS patients with OPTN mutations included 20 males and 16 females with another patient whose gender was not described. The mean onset age of 37 ALS12 patients was 48 with the youngest 23 and the oldest 83 years old. Differences in onset age between male and female patients were not significant. Mean time from initiation to death was 61.8 &#xb1; 12.0 months. Patients present with either limb onset (73.5% cases) or bulbar onset (23.5% cases).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Through the literature review, we summarized the clinical characteristics of ALS12. The phenotypes of the reported patients elucidate the genetic profiles and clinical phenotypes of ALS12. Clinicians should pay close attention to the role of receptor-interacting kinase 1 (RIPK1)-dependent necroptosis in the pathophysiologic development of ALS12, since necroptosis inhibitors are expected as potential therapeutic agents for treating ALS12.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mou</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neural Regeneration and Repair, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neural Regeneration and Repair, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mengling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neural Regeneration and Repair, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neural Regeneration and Repair, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Guofeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neural Regeneration and Repair, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zha</LastName><ForeName>Yunhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China. yzha7808@ctgu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neural Regeneration and Repair, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, 443000, China. yzha7808@ctgu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035582">Transcription Factor TFIIIA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035582" MajorTopicYN="Y">Transcription Factor TFIIIA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Necroptosis</Keyword><Keyword MajorTopicYN="N">Optineurin (OPTN)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35661277</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06125-5</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06125-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adaniya SM, O-Uchi J, Cypress MW, Kusakari Y (2019) Jhun BS (2019) Posttranslational modifications of mitochondrial fission and fusion proteins in cardiac physiology and pathophysiology. Am J Physiol Cell Physiol 316:C583&#x2013;C604. https://doi.org/10.1152/ajpcell.00523.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00523.2018</ArticleId><ArticleId IdType="pubmed">30758993</ArticleId><ArticleId IdType="pmc">6580160</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovic D, Vucic D, Dikic I (2014) Ubiquitination in disease pathogenesis and treatment. Nat Med 20:1242&#x2013;1253. https://doi.org/10.1038/nm.3739</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3739</ArticleId><ArticleId IdType="pubmed">25375928</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas P, Ramirez AI, Fernandez-Albarral JA, Lopez-Cuenca I, Salobrar-Garcia E, Cadena M et al (2020) Amyotrophic lateral sclerosis: a neurodegenerative motor neuron disease with ocular involvement. Front Neurosci 2020 14: 566858. https://doi.org/10.3389/fnins.2020.566858</Citation></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y et al (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465(7295):223&#x2013;226. https://doi.org/10.1038/nature08971</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y et al (2016) RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353(6299):603&#x2013;608. https://doi.org/10.1126/science.aaf6803</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId><ArticleId IdType="pmc">5444917</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 124 Suppl:96-107. https://doi.org/10.1016/0022-510x(94)90191-0</Citation></Reference><Reference><Citation>Orsini M, Oliveira AB, Nascimento OJ, Reis CH, Leite MA, de Souza JA et al (2015) Amyotrophic lateral sclerosis: new perpectives and update. Neurol Int 7(2):5885. https://doi.org/10.4081/ni.2015.5885</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ni.2015.5885</ArticleId><ArticleId IdType="pubmed">26487927</ArticleId><ArticleId IdType="pmc">4591493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapin JL, Gray LT, Vasilopoulos T, Anderson A, DiBiase L, York JD et al (2020) Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis. PLoS ONE 15(8):e0236804. https://doi.org/10.1371/journal.pone.0236804</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236804</ArticleId><ArticleId IdType="pubmed">32790801</ArticleId><ArticleId IdType="pmc">7425890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BH, Lee JC, Lee SM, Park Y, Ryu JS (2019) Application of automatic kinematic analysis program for the evaluation of dysphagia in ALS patients. Sci Rep 9(1):15644. https://doi.org/10.1038/s41598-019-52246-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-52246-x</ArticleId><ArticleId IdType="pubmed">31666678</ArticleId><ArticleId IdType="pmc">6821821</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73(15):1218&#x2013;1226. https://doi.org/10.1212/WNL.0b013e3181bc0141</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId><ArticleId IdType="pmc">2764727</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405&#x2013;424. https://doi.org/10.1038/gim.2015.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId><ArticleId IdType="pmc">4544753</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;mer Z, Bertelsen B, Gredal O, Magyari M, Nielsen KC, LuCamp et al (2015) A novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS. Neurobiol Aging 33(1):208.e1-5. 10.1016/j.neurobiolaging.2011.07.001</Citation></Reference><Reference><Citation>Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1:112&#x2013;119. https://doi.org/10.1038/nchembio711</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio711</ArticleId><ArticleId IdType="pubmed">16408008</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofferson DE, Yuan J (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22:263&#x2013;268. https://doi.org/10.1016/j.ceb.2009.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2009.12.003</ArticleId><ArticleId IdType="pubmed">20045303</ArticleId><ArticleId IdType="pmc">2854308</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>